FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018367620> ?p ?o ?g. }

• W2018367620 endingPage "994" @default.
• W2018367620 startingPage "986" @default.
• W2018367620 abstract "The purpose of this study was to assess the safety, tolerability and impact on overactive bladder (OAB) symptoms of a novel combination of tolterodine immediate-release (IR) 2 mg and delayed-release pilocarpine 9 mg in patients with OAB.Eligible patients with OAB were randomised to each of three treatments [tolterodine/pilocarpine (2/9 mg), tolterodine IR 2 mg or placebo] twice daily for 4 weeks in a double-blind, crossover fashion. At the end of the 12-week, double-blind treatment period, patients could enter an open-label extension during which they were re-randomised to either tolterodine/pilocarpine (3/13.5 mg) twice daily or tolterodine extended-release 4 mg once daily for 12 weeks.A total of 138 patients were randomised to double-blind medication. Both tolterodine/pilocarpine (2/9) and tolterodine IR 2 mg significantly reduced incontinence episodes and daily micturitions (p < 0.001 vs. placebo), with similar reductions in symptoms observed between active treatment groups. Tolterodine/pilocarpine (2/9) was associated with consistently lower Visual Analogue Scale (VAS) scores for all dry mouth parameters compared with tolterodine alone. Salivary flow over a 3 h period remained fairly constant after tolterodine/pilocarpine (2/9) administration, similar to placebo, but decreased markedly after administration of tolterodine alone. In the extension study, patients receiving tolterodine/pilocarpine (3/13.5) reported comparable dry mouth VAS scores to tolterodine extended-release alone without additional side effects or loss of efficacy. The combination was well tolerated, and the adverse effects observed were consistent with the known safety profiles of tolterodine and pilocarpine.A combination of tolterodine/pilocarpine (2/9) effectively reduced the incidence of dry mouth compared with tolterodine IR alone while maintaining treatment efficacy in OAB." @default.
• W2018367620 created "2016-06-24" @default.
• W2018367620 creator A5024705146 @default.
• W2018367620 creator A5042646128 @default.
• W2018367620 creator A5050079693 @default.
• W2018367620 creator A5053685634 @default.
• W2018367620 creator A5064693560 @default.
• W2018367620 date "2014-03-25" @default.
• W2018367620 modified "2023-10-13" @default.
• W2018367620 title "Clinical safety, tolerability and efficacy of combination tolterodine/pilocarpine in patients with overactive bladder" @default.
• W2018367620 cites W1585489386 @default.
• W2018367620 cites W1603915265 @default.
• W2018367620 cites W1967340813 @default.
• W2018367620 cites W1984095947 @default.
• W2018367620 cites W2001275235 @default.
• W2018367620 cites W2003679722 @default.
• W2018367620 cites W2012563222 @default.
• W2018367620 cites W2017920228 @default.
• W2018367620 cites W2026599479 @default.
• W2018367620 cites W2040078984 @default.
• W2018367620 cites W2052649818 @default.
• W2018367620 cites W2054263301 @default.
• W2018367620 cites W2059240022 @default.
• W2018367620 cites W2064365016 @default.
• W2018367620 cites W2071231390 @default.
• W2018367620 cites W2088252790 @default.
• W2018367620 cites W2089648313 @default.
• W2018367620 cites W2104695082 @default.
• W2018367620 cites W2105391780 @default.
• W2018367620 cites W2114213251 @default.
• W2018367620 cites W2116324813 @default.
• W2018367620 cites W2131173377 @default.
• W2018367620 cites W2131770336 @default.
• W2018367620 cites W2133603145 @default.
• W2018367620 cites W2134928141 @default.
• W2018367620 doi "https://doi.org/10.1111/ijcp.12409" @default.
• W2018367620 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24666884" @default.
• W2018367620 hasPublicationYear "2014" @default.
• W2018367620 type Work @default.
• W2018367620 sameAs 2018367620 @default.
• W2018367620 citedByCount "18" @default.
• W2018367620 countsByYear W20183676202014 @default.
• W2018367620 countsByYear W20183676202015 @default.
• W2018367620 countsByYear W20183676202016 @default.
• W2018367620 countsByYear W20183676202017 @default.
• W2018367620 countsByYear W20183676202018 @default.
• W2018367620 countsByYear W20183676202019 @default.
• W2018367620 countsByYear W20183676202020 @default.
• W2018367620 countsByYear W20183676202023 @default.
• W2018367620 crossrefType "journal-article" @default.
• W2018367620 hasAuthorship W2018367620A5024705146 @default.
• W2018367620 hasAuthorship W2018367620A5042646128 @default.
• W2018367620 hasAuthorship W2018367620A5050079693 @default.
• W2018367620 hasAuthorship W2018367620A5053685634 @default.
• W2018367620 hasAuthorship W2018367620A5064693560 @default.
• W2018367620 hasBestOaLocation W20183676201 @default.
• W2018367620 hasConcept C118552586 @default.
• W2018367620 hasConcept C126322002 @default.
• W2018367620 hasConcept C126894567 @default.
• W2018367620 hasConcept C142724271 @default.
• W2018367620 hasConcept C197934379 @default.
• W2018367620 hasConcept C204787440 @default.
• W2018367620 hasConcept C27081682 @default.
• W2018367620 hasConcept C2777204577 @default.
• W2018367620 hasConcept C2778186239 @default.
• W2018367620 hasConcept C2778375690 @default.
• W2018367620 hasConcept C2778941218 @default.
• W2018367620 hasConcept C2781020410 @default.
• W2018367620 hasConcept C42219234 @default.
• W2018367620 hasConcept C71924100 @default.
• W2018367620 hasConceptScore W2018367620C118552586 @default.
• W2018367620 hasConceptScore W2018367620C126322002 @default.
• W2018367620 hasConceptScore W2018367620C126894567 @default.
• W2018367620 hasConceptScore W2018367620C142724271 @default.
• W2018367620 hasConceptScore W2018367620C197934379 @default.
• W2018367620 hasConceptScore W2018367620C204787440 @default.
• W2018367620 hasConceptScore W2018367620C27081682 @default.
• W2018367620 hasConceptScore W2018367620C2777204577 @default.
• W2018367620 hasConceptScore W2018367620C2778186239 @default.
• W2018367620 hasConceptScore W2018367620C2778375690 @default.
• W2018367620 hasConceptScore W2018367620C2778941218 @default.
• W2018367620 hasConceptScore W2018367620C2781020410 @default.
• W2018367620 hasConceptScore W2018367620C42219234 @default.
• W2018367620 hasConceptScore W2018367620C71924100 @default.
• W2018367620 hasIssue "8" @default.
• W2018367620 hasLocation W20183676201 @default.
• W2018367620 hasLocation W20183676202 @default.
• W2018367620 hasOpenAccess W2018367620 @default.
• W2018367620 hasPrimaryLocation W20183676201 @default.
• W2018367620 hasRelatedWork W1983371621 @default.
• W2018367620 hasRelatedWork W1983573081 @default.
• W2018367620 hasRelatedWork W1996534025 @default.
• W2018367620 hasRelatedWork W2001645992 @default.
• W2018367620 hasRelatedWork W2019380449 @default.
• W2018367620 hasRelatedWork W2050061619 @default.
• W2018367620 hasRelatedWork W2065591897 @default.
• W2018367620 hasRelatedWork W2084288786 @default.
• W2018367620 hasRelatedWork W2089437227 @default.

• next